Research graph
References from Fast-Dissolving and Highly Soluble Dasatinib Multicomponent Crystals Efficiently Inhibit Leukemia Cell Viability. Local targets link to admitted publications; unresolved targets remain external evidence.
Salt Formation to Improve Drug Solubility
10.1016/j.addr.2007.05.010 · 2007 · External reference
Pharmaceutical Cocrystals, Salts and Multicomponent Systems; Intermolecular Interactions and Property Based Design
10.1016/j.addr.2017.03.003 · 2017 · External reference
Crystal Engineering of Active Pharmaceutical Ingredients to Improve Solubility and Dissolution Rates
10.1016/j.addr.2007.05.011 · 2007 · External reference
Crystal Engineering: From Promise to Delivery
10.1039/d3cc04313d · 2023 · External reference
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
10.1021/acs.chemrev.1c00987 · 2022 · External reference
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals
10.15171/apb.2018.042 · 2018 · External reference
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development
10.15171/apb.2016.062 · 2016 · External reference
Pharmaceutical Co-Crystals: A Green Way to Enhance Drug Stability and Solubility for Improved Therapeutic Efficacy
10.1093/jpp/rgad097 · 2024 · External reference
Pharmaceutical Cocrystallization: An Effective Approach to Modulate the Physicochemical Properties of Solid-State Drugs
10.1039/c8ce00707a · 2018 · External reference
Use of Pharmaceutical Salts and Cocrystals to Address the Issue of Poor Solubility
10.1016/j.ijpharm.2012.11.028 · 2013 · External reference
Pharmaceutical Cocrystals: Along the Path to Improved Medicines
10.1039/c5cc08216a · 2016 · External reference
Multi-Component Crystal Strategy for Improving Water Solubility and Antifungal Activity of Climbazole
10.1007/s11095-024-03748-5 · 2024 · External reference
Multicomponent Solid Forms of Pioglitazone and Their Influence on Drug Dissolution
10.1021/acs.cgd.4c01617 · 2025 · External reference
A Review of Coformer Utilization in Multicomponent Crystal Formation
10.3390/molecules27248693 · 2022 · External reference
The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
10.1158/0008-5472.can-05-4187 · 2006 · External reference
Phase I Study of the Effect of Gastric Acid PH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
10.1177/0091270009333854 · 2009 · External reference
Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: From Systemic Limitations to Targeted Success
10.1208/s12249-025-03130-7 · 2025 · External reference
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
10.1007/s40262-020-00872-4 · 2020 · External reference
Cocrystallization of Dasatinib with Different Acids Improves the Solubility and Physicochemical Properties: A Combined Experimental and Theoretical Studies
10.1016/j.chphi.2023.100247 · 2023 · External reference
Insight into the Formation of Heteromolecular Hydrogen Bonds between Dasatinib and GRAS Molecules
10.1021/acs.oprd.0c00549 · 2021 · External reference
Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders
10.3390/ijms20030591 · 2019 · External reference
Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery
10.3390/pharmaceutics14010197 · 2022 · External reference
Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
10.3390/pharmaceutics14112450 · 2022 · External reference
Enhancing Oral Bioavailability of Dasatinib via Supersaturable SNEDDS: Investigation of Precipitation Inhibition and IVIVC through in-Vitro Lipolysis-Permeation Model
10.1016/j.ijpharm.2024.125007 · 2025 · External reference
Development, Optimization, and Characterization of Polymeric Micelles to Improve Dasatinib Oral Bioavailability: Hep G2 Cell Cytotoxicity and in Vivo Pharmacokinetics for Targeted Liver Cancer Therapy
10.1016/j.heliyon.2024.e39632 · 2024 · External reference
Study on Tumour Cell-Derived Hybrid Exosomes as Dasatinib Nanocarriers for Pancreatic Cancer Therapy
10.1080/21691401.2023.2264358 · 2023 · External reference
Solvates of Dasatinib: Diversity and Isostructurality
10.1016/j.xphs.2016.01.024 · 2016 · External reference
Similarity and Differences of Dasatinib Solvates: A Crystallographic Perspective
10.1021/acs.cgd.4c00248 · 2024 · External reference
Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
10.1021/acsomega.1c06753 · 2022 · External reference
OLEX2: A Complete Structure Solution, Refinement and Analysis Program
10.1107/s0021889808042726 · 2009 · External reference
SHELXT - Integrated Space-Group and Crystal-Structure Determination
10.1107/s2053273314026370 · 2015 · External reference
Crystal Structure Refinement with SHELXL
10.1107/s2053229614024218 · 2015 · External reference
PLATON SQUEEZE: A Tool for the Calculation of the Disordered Solvent Contribution to the Calculated Structure Factors
10.1107/s2053229614024929 · 2015 · External reference
Mercury 4.0: From Visualization to Analysis, Design and Prediction
10.1107/s1600576719014092 · 2020 · External reference
CrystalExplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals
10.1107/s1600576721002910 · 2021 · External reference
The Cambridge Structural Database
10.1107/s2052520616003954 · 2016 · External reference
Unresolved reference
2005 · External reference
Comparison of a Miniaturized Shake-Flask Solubility Method with Automated Potentiometric Acid/Base Titrations and Calculated Solubilities
10.1002/jps.20212 · 2005 · External reference
Unresolved reference
1998 · External reference
Acid–Base Crystalline Complexes and the PKa Rule
10.1039/c2ce26055g · 2012 · External reference
The Role of Solvation in Proton Transfer Reactions: Implications for Predicting Salt/Co-Crystal Formation Using the ΔpKa Rule
10.1039/d1fd00081k · 2022 · External reference
Structural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate Phases
10.1021/cg300152p · 2012 · External reference
Analysis of Solid-State Transformations of Pharmaceutical Compounds Using Vibrational Spectroscopy
10.1211/jpp.61.08.0001 · 2009 · External reference
Synthesis Crystal Structure and Biological Evaluation of a New Dasatinib Copper(II) Complex as Telomerase Inhibitor
10.1016/j.ejmech.2017.10.058 · 2018 · External reference
A Bioorthogonal Approach for Imaging the Binding between Dasatinib and Its Target Proteins inside Living Cells
10.1039/c6cc07011f · 2016 · External reference
Applications of Powder X-Ray Diffraction in Small Molecule Pharmaceuticals: Achievements and Aspirations
10.1016/j.xphs.2018.08.010 · 2018 · External reference
Strategies to Address Low Drug Solubility in Discovery and Development
10.1124/pr.112.005660 · 2013 · External reference
Contribution of ABCC4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
10.1158/1078-0432.ccr-13-0980 · 2013 · External reference
Spring and Parachute: How Cocrystals Enhance Solubility
10.1016/j.pcrysgrow.2016.07.001 · 2016 · External reference
Energy Framework and Solubility: A New Predictive Model in the Evaluation of the Structure-Property Relationship of Pharmaceutical Solid Forms
10.1039/d2ce00818a · 2022 · External reference
Unresolved reference
2009 · External reference
Comparison of a Miniaturized Shake-Flask Solubility Method with Automated Potentiometric Acid/Base Titrations and Calculated Solubilities
10.1002/jps.20212 · ExternalCitation · doi-reference
Multi-Component Crystal Strategy for Improving Water Solubility and Antifungal Activity of Climbazole
10.1007/s11095-024-03748-5 · ExternalCitation · doi-reference
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
10.1007/s40262-020-00872-4 · ExternalCitation · doi-reference
Salt Formation to Improve Drug Solubility
10.1016/j.addr.2007.05.010 · ExternalCitation · doi-reference
Crystal Engineering of Active Pharmaceutical Ingredients to Improve Solubility and Dissolution Rates
10.1016/j.addr.2007.05.011 · ExternalCitation · doi-reference
Pharmaceutical Cocrystals, Salts and Multicomponent Systems; Intermolecular Interactions and Property Based Design
10.1016/j.addr.2017.03.003 · ExternalCitation · doi-reference
Cocrystallization of Dasatinib with Different Acids Improves the Solubility and Physicochemical Properties: A Combined Experimental and Theoretical Studies
10.1016/j.chphi.2023.100247 · ExternalCitation · doi-reference
Synthesis Crystal Structure and Biological Evaluation of a New Dasatinib Copper(II) Complex as Telomerase Inhibitor
10.1016/j.ejmech.2017.10.058 · ExternalCitation · doi-reference
Development, Optimization, and Characterization of Polymeric Micelles to Improve Dasatinib Oral Bioavailability: Hep G2 Cell Cytotoxicity and in Vivo Pharmacokinetics for Targeted Liver Cancer Therapy
10.1016/j.heliyon.2024.e39632 · ExternalCitation · doi-reference
Use of Pharmaceutical Salts and Cocrystals to Address the Issue of Poor Solubility
10.1016/j.ijpharm.2012.11.028 · ExternalCitation · doi-reference
Enhancing Oral Bioavailability of Dasatinib via Supersaturable SNEDDS: Investigation of Precipitation Inhibition and IVIVC through in-Vitro Lipolysis-Permeation Model
10.1016/j.ijpharm.2024.125007 · ExternalCitation · doi-reference
Spring and Parachute: How Cocrystals Enhance Solubility
10.1016/j.pcrysgrow.2016.07.001 · ExternalCitation · doi-reference
Solvates of Dasatinib: Diversity and Isostructurality
10.1016/j.xphs.2016.01.024 · ExternalCitation · doi-reference
Applications of Powder X-Ray Diffraction in Small Molecule Pharmaceuticals: Achievements and Aspirations
10.1016/j.xphs.2018.08.010 · ExternalCitation · doi-reference
Similarity and Differences of Dasatinib Solvates: A Crystallographic Perspective
10.1021/acs.cgd.4c00248 · ExternalCitation · doi-reference
Multicomponent Solid Forms of Pioglitazone and Their Influence on Drug Dissolution
10.1021/acs.cgd.4c01617 · ExternalCitation · doi-reference
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
10.1021/acs.chemrev.1c00987 · ExternalCitation · doi-reference
Insight into the Formation of Heteromolecular Hydrogen Bonds between Dasatinib and GRAS Molecules
10.1021/acs.oprd.0c00549 · ExternalCitation · doi-reference
Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
10.1021/acsomega.1c06753 · ExternalCitation · doi-reference
Structural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate Phases
10.1021/cg300152p · ExternalCitation · doi-reference
Acid–Base Crystalline Complexes and the PKa Rule
10.1039/c2ce26055g · ExternalCitation · doi-reference
Pharmaceutical Cocrystals: Along the Path to Improved Medicines
10.1039/c5cc08216a · ExternalCitation · doi-reference
A Bioorthogonal Approach for Imaging the Binding between Dasatinib and Its Target Proteins inside Living Cells
10.1039/c6cc07011f · ExternalCitation · doi-reference
Pharmaceutical Cocrystallization: An Effective Approach to Modulate the Physicochemical Properties of Solid-State Drugs
10.1039/c8ce00707a · ExternalCitation · doi-reference
The Role of Solvation in Proton Transfer Reactions: Implications for Predicting Salt/Co-Crystal Formation Using the ΔpKa Rule
10.1039/d1fd00081k · ExternalCitation · doi-reference
Energy Framework and Solubility: A New Predictive Model in the Evaluation of the Structure-Property Relationship of Pharmaceutical Solid Forms
10.1039/d2ce00818a · ExternalCitation · doi-reference
Crystal Engineering: From Promise to Delivery
10.1039/d3cc04313d · ExternalCitation · doi-reference
Study on Tumour Cell-Derived Hybrid Exosomes as Dasatinib Nanocarriers for Pancreatic Cancer Therapy
10.1080/21691401.2023.2264358 · ExternalCitation · doi-reference
Pharmaceutical Co-Crystals: A Green Way to Enhance Drug Stability and Solubility for Improved Therapeutic Efficacy
10.1093/jpp/rgad097 · ExternalCitation · doi-reference
OLEX2: A Complete Structure Solution, Refinement and Analysis Program
10.1107/s0021889808042726 · ExternalCitation · doi-reference
Mercury 4.0: From Visualization to Analysis, Design and Prediction
10.1107/s1600576719014092 · ExternalCitation · doi-reference
CrystalExplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals
10.1107/s1600576721002910 · ExternalCitation · doi-reference
The Cambridge Structural Database
10.1107/s2052520616003954 · ExternalCitation · doi-reference
Crystal Structure Refinement with SHELXL
10.1107/s2053229614024218 · ExternalCitation · doi-reference
PLATON SQUEEZE: A Tool for the Calculation of the Disordered Solvent Contribution to the Calculated Structure Factors
10.1107/s2053229614024929 · ExternalCitation · doi-reference
SHELXT - Integrated Space-Group and Crystal-Structure Determination
10.1107/s2053273314026370 · ExternalCitation · doi-reference
Strategies to Address Low Drug Solubility in Discovery and Development
10.1124/pr.112.005660 · ExternalCitation · doi-reference
The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
10.1158/0008-5472.can-05-4187 · ExternalCitation · doi-reference
Contribution of ABCC4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
10.1158/1078-0432.ccr-13-0980 · ExternalCitation · doi-reference
Phase I Study of the Effect of Gastric Acid PH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
10.1177/0091270009333854 · ExternalCitation · doi-reference
Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: From Systemic Limitations to Targeted Success
10.1208/s12249-025-03130-7 · ExternalCitation · doi-reference
Analysis of Solid-State Transformations of Pharmaceutical Compounds Using Vibrational Spectroscopy
10.1211/jpp.61.08.0001 · ExternalCitation · doi-reference
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development
10.15171/apb.2016.062 · ExternalCitation · doi-reference
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals
10.15171/apb.2018.042 · ExternalCitation · doi-reference
Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders
10.3390/ijms20030591 · ExternalCitation · doi-reference
A Review of Coformer Utilization in Multicomponent Crystal Formation
10.3390/molecules27248693 · ExternalCitation · doi-reference
Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery
10.3390/pharmaceutics14010197 · ExternalCitation · doi-reference
Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
10.3390/pharmaceutics14112450 · ExternalCitation · doi-reference
